Skip to content
10-K

Annual Report

GlobeStar Therapeutics Corp

0001161697-24-000049

← back to feed
Filed
Jan 19, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2023 · Jan 16, 2024 1.03B sh
Operating Cash Flow FY 2023 · Sep 30, 2023 −$205.76K
Operating Cash Flow FY 2023 · Sep 30, 2022 −$327K
Stockholders Equity FY 2023 · Sep 30, 2023 −$1.43M
Stockholders Equity FY 2023 · Sep 30, 2022 −$1.19M
Stockholders Equity FY 2023 · Sep 30, 2021 −$725.82K
Current Liabilities FY 2023 · Sep 30, 2023 $1.43M
Current Liabilities FY 2023 · Sep 30, 2022 $1.2M
Total Liabilities FY 2023 · Sep 30, 2023 $1.43M
Total Liabilities FY 2023 · Sep 30, 2022 $1.2M
Rd Expense FY 2023 · Sep 30, 2023 $0
Rd Expense FY 2023 · Sep 30, 2022 $0
Net Income FY 2023 · Sep 30, 2023 −$1.95M
Net Income FY 2023 · Sep 30, 2022 −$1.49M
Operating Income FY 2023 · Sep 30, 2023 −$1.86M
Operating Income FY 2023 · Sep 30, 2022 −$1.27M
Cash And Equivalents FY 2023 · Sep 30, 2022 $6.37K
Current Assets FY 2023 · Sep 30, 2022 $9.92K
Total Assets FY 2023 · Sep 30, 2022 $9.92K
Stock Issued FY 2023 · Feb 28, 2022 6M sh